Additional tissue correlatives from a neoadjuvant phase 2 trial of sitravatinib plus nivolumab in patients with ccRCC demonstrated upregulation of the interferon gamma (IFN-γ) response pathway which may additionally sensitize tumors to anti-CTLA-4 ICT7. This evidence concerns the gene IFNG and nonpapillary renal cell carcinoma.